Clinical Features, Treatment and Prognostic Factors of Childhood-onset Myasthenia Gravis in A Large Chinese Cohort
Zhuajin Bi,Huizhen Ge,Qing Zhang,Huajie Gao,Mengge Yang,Jiayang Zhan,Jing Lin,Mengcui Gui,Yue Li,Suqiong Ji,Yayun Cao,Bitao Bu
DOI: https://doi.org/10.1016/j.pediatrneurol.2023.06.008
IF: 4.21
2023-06-17
Pediatric Neurology
Abstract:Objectives To describe the clinical features of childhood-onset myasthenia gravis (CMG) patients and explore predictors affecting the treatment outcomes. Methods A retrospective, observational cohort analysis of 859 CMG patients with disease onset before the age of 14 years were performed at Tongji Hospital. Results Patients in the pubertal onset group (n=148) had a worse disease course than those in the prepubertal group (n=711), including a higher incidence of generalized MG (GMG) at presentation, generalization of ocular MG (OMG), and more severe Myasthenia Gravis Foundation of America (MGFA) classification. All patients were initially treated with pyridostigmine, 657 with prednisone, and 196 with immunosuppressants. However, 226 patients were resistant to prednisone treatment. Multivariate analysis revealed that thymic hyperplasia, higher MGFA class, disease duration before prednisone administration, and thymectomy before prednisone administration were independent predictors of prednisone resistance. At the last visit, 121 out of the 840 OMG patients had developed GMG after a median of 10.0 years from symptom onset, and 186 patients (21.7%) achieved complete stable remission (CSR). In multivariable analysis, age at onset, thymic hyperplasia, prednisone, and IS treatment were associated with generalization; while age at onset, disease duration, anti-acetylcholine receptor antibodies (AChR-ab), MGFA class II, short-term prednisone treatment, and IS treatment were associated with CSR. Conclusions The majority of CMG patients have mild clinical symptoms and favorable outcomes, especially those with earlier onset age, shorter disease duration, and negative AChR-ab. In addition, early prednisone and IS are shown to be effective and safe for most CMG patients.
pediatrics,clinical neurology